Baxdrostat + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uncontrolled Hypertension

Conditions

Uncontrolled Hypertension

Trial Timeline

Jun 10, 2024 → Dec 4, 2024

NCT ID

NCT06336356

About Baxdrostat + Placebo

Baxdrostat + Placebo is a phase 2 stage product being developed by AstraZeneca for Uncontrolled Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT06336356. Target conditions include Uncontrolled Hypertension.

What happened to similar drugs?

4 of 11 similar drugs in Uncontrolled Hypertension were approved

Approved (4) Terminated (0) Active (7)

✅Pegloticase + Methotrexate (MTX)AmgenApproved

✅PegloticaseAmgenApproved

✅Pegloticase + Methotrexate (MTX)AmgenApproved

✅Pegloticase with MTXAmgenApproved

🔄HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3

🔄Baxdrostat + PlaceboAstraZenecaPhase 3

🔄TralokinumabAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07007793	Phase 3	Recruiting	Aug 7, 2025	Feb 18, 2028	Primary Hyperaldosteronism
NCT06336356	Phase 2	Completed	Jun 10, 2024	Dec 4, 2024	Uncontrolled Hypertension
NCT06344104	Phase 3	Active	Apr 8, 2024	Apr 3, 2026	Uncontrolled Hypertension
NCT06168409	Phase 3	Completed	Mar 1, 2024	Aug 17, 2025	Resistant Hypertension
NCT06034743	Phase 3	Completed	Nov 22, 2023	Oct 10, 2025	Uncontrolled Hypertension

Competing Products

17 competing products in Uncontrolled Hypertension

See all competitors

Product	Company	Stage	Hype Score
KHK4563 + KHK4563 + KHK4563 + Placebo	Kyowa Kirin	Phase 2	35
HR17031 injection + insulin glargine	Jiangsu Hengrui Medicine	Phase 3	40
Baxdrostat + Placebo	AstraZeneca	Phase 3	44
Tralokinumab	AstraZeneca	Phase 3	40
Baxdrostat + Placebo	AstraZeneca	Phase 3	40
Benralizumab	AstraZeneca	Phase 3	40
Experimental: Tralokinumab	AstraZeneca	Phase 3	40
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E	AstraZeneca	Phase 1	29
CIN-107 + Placebo	AstraZeneca	Phase 2	35
Pegloticase + Methotrexate (MTX)	Amgen	Approved	43
Pegloticase	Amgen	Approved	43
Pegloticase + Methotrexate	Amgen	Phase 3	47
Pegloticase + Methotrexate (MTX)	Amgen	Approved	43
Pegloticase with MTX	Amgen	Approved	43
abrocitinib	Pfizer	Pre-clinical	30
REGN5381 + Placebo	Regeneron Pharmaceuticals	Phase 2	27
SAL0140 + SAL0140 placebo	Shenzhen Salubris Pharmaceuticals	Phase 1	36